Analysts Offer Predictions for THTX FY2027 Earnings

Theratechnologies Inc. (NASDAQ:THTX - Free Report) - Equities researchers at Leede Financial issued their FY2027 EPS estimates for shares of Theratechnologies in a research report issued to clients and investors on Wednesday, February 26th. Leede Financial analyst D. Loe anticipates that the company will earn $0.23 per share for the year. The consensus estimate for Theratechnologies' current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies' FY2027 earnings at $0.23 EPS.

Separately, Research Capitl upgraded Theratechnologies to a "strong-buy" rating in a research report on Friday, February 14th.

Theratechnologies Trading Down 2.4 %

Shares of Theratechnologies stock traded down $0.04 on Friday, reaching $1.60. 132,431 shares of the stock were exchanged, compared to its average volume of 119,969. The firm has a market capitalization of $73.57 million, a PE ratio of -16.00 and a beta of 1.26. Theratechnologies has a 1-year low of $1.08 and a 1-year high of $2.18. The business has a fifty day moving average price of $1.74 and a two-hundred day moving average price of $1.46.

Institutional Investors Weigh In On Theratechnologies

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. National Bank of Canada FI increased its holdings in shares of Theratechnologies by 29.4% in the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company's stock valued at $232,000 after purchasing an additional 42,435 shares in the last quarter. Wealthspire Advisors LLC grew its position in Theratechnologies by 39.0% during the fourth quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company's stock worth $129,000 after buying an additional 20,000 shares during the period. Raymond James Financial Inc. purchased a new position in Theratechnologies in the fourth quarter valued at about $27,000. Harbour Investments Inc. lifted its position in shares of Theratechnologies by 20.0% during the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company's stock valued at $159,000 after acquiring an additional 14,655 shares during the period. Finally, Virtu Financial LLC acquired a new stake in shares of Theratechnologies in the 4th quarter worth approximately $40,000.

Remove Ads

About Theratechnologies

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.